DRGT 100Alternative Names: DRGT-100
Latest Information Update: 08 Dec 2016
At a glance
- Originator Druggability Technologies
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chronic lymphocytic leukaemia
Most Recent Events
- 07 Dec 2016 Preclinical trials in Chronic lymphocytic leukaemia in Hungary (unspecified route)